|
1) Borbely A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005; 111: 774-81
|
|
|
|
2) van Heerebeek L, Borbely A, Niessen HWM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006; 113: 1966-73
|
|
|
|
|
|
3) Lam CSP, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007; 115: 1982-90
|
|
|
|
|
|
4) Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006; 355: 260-9
|
|
|
|
|
|
5) Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006; 355: 251-9
|
|
|
|
|
|
6) Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA. 2006; 296: 2209-16
|
|
|
|
|
|
7) Aurigemma GP. Diastolic heart failure - a common and lethal condition by any name. N Engl J Med. 2006; 355: 308-10
|
|
|
|
|
|
8) Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. J Am Coll Cardiol. 2006; 47: 1997-2004
|
|
|
|
|
|
9) Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113: 671-8
|
|
|
|
|
|
10) Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserv-ed systolic function. J Am Coll Cardiol. 2006; 47: 76-84
|
|
|
|
|
|
11) Persson H, Lonn E, Edner M, et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence. J Am Coll Cardiol. 2007; 49: 687-94
|
|
|
|
|
|
12) Valle R, Aspromonte N, Feola M, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail. 2005; 11: 498-503
|
|
|
|
|
|
13) Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 777-81
|
|
|
|
|
|
14) The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology. Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005). Eur Heart J. 2005; European Society of Cardiology Web site :http://www.escardio.org/NR/rdonlyres/8A2848B4-5DEB-41B9-9A0A-5B5A90494B64/0/CHFFullTextehi205FVFW170505.pdf
|
|
|
|
|
|
15) Adams KFJ, Lindenfeld J, Arnold JMO, et al. Executive summary: HFSA 2006 Comprehensive heart failure practice guideline. J Card Fail. 2006; 12: 10-38
|
|
|
|
|
|
16) Yoshida J, Yamamoto K, Mano T, et al. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension. 2004; 43: 686-91
|
|
|
|
|
|
17) Carson P, Massie BM, Mckelvie R, et al. The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005; 11: 576-85
|
|
|
|
|
|
18) Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27: 2338-45
|
|
|
|
|
|
19) Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail. 2004; 6: 453-61
|
|
|
|
|
|
20) Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospi-tal admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26: 215-25
|
|
|
|
|
|
21) The J-DHF Program Committee. Rationale and design of a randomized trial to assess the effects of beta-blocker in diastolic heart failure: Japanese Diastolic Heart Failure Study (J-DHF). J Card Fail. 2005; 11: 542-7
|
|
|
|
|
|
22) Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006; 114: 397-403
|
|
|
|
|
|
23) Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006; 27: 178-86
|
|
|
|
|
|
24) Ohtani T, Ohta M, Yamamoto K, et al. Elevated cardiac tissue level of aldosterone and mineralo-corticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol. 2007; 292: R946-54
|
|
|
|
|
|
25) Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004; 110: 558-65
|
|
|
|
|
|
26) Little WC, Zile M, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005; 11: 191-5
|
|
|
|
|
|
27) Fukuta H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. Circulation. 2005; 112: 357-63
|
|
|
|
|